Revvity Inc’s shares advanced to a 52-week high of $122.26 on Wednesday, closing at $122.10, as second-quarter results exceeded Wall Street expectations.
The life sciences technology provider reported adjusted earnings per share of $1.41, surpassing the $1.21 consensus estimate, while revenue reached $729.68 million against a $703.39 million forecast. The company also recorded $16 million in tariff refunds and advanced tax savings, contributing to the upside.
Year-to-date, Revvity’s stock has gained 24%, extending its six-month advance to 19%, while the 12-month return stands at 35.59%. The company’s market capitalization reached $13.52 billion, with a P/E ratio of 57.
Revvity cited stronger organic growth, expanding margins and rising demand tied to artificial intelligence as key drivers of its performance. However, Stifel maintained a Hold rating on the shares despite raising its price target to $110 from its prior level.
Premarket trading showed the stock slipping after the earnings release, as investors questioned the durability of the earnings beat. InvestingPro analysis characterized the shares as overvalued relative to fair value estimates.
The company’s strong financial performance contrasts with broader market caution over valuation sustainability in high-growth sectors.
